Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | BMC Cancer |
| Vol/bind | 10 |
| Sider (fra-til) | 677 |
| Antal sider | 13 |
| ISSN | 1471-2407 |
| DOI | |
| Status | Udgivet - 10 dec. 2010 |
- Det Sundhedsvidenskabelige Fakultet
Forskningsområder
ID: 32331205